HealthTree

Showing 270 trials matching your filters.

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refra...

This phase I trial studies the side effects and best dose of palbociclib when given alone and in combination with sorafenib, decitabine, or dexamethasone in treating patients with leukemia that has come back (recurrent) or that does not respond to pr...

DRUG: Decitabine

DRUG: Dexamethasone

DRUG: Palbociclib

DRUG: Sorafenib

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acut...

This phase I trial studies the side effects and best dose of ivosidenib when given together with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refracto...

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Fludarabine Phosphate

DRUG: Ivosidenib

A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Le...

The researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations. The researchers will al...

DRUG: Gilteritinib

DRUG: Ivosidenib

DRUG: Enasidenib

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute...

This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the toler...

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Cytarabine

DRUG: Gemtuzumab Ozogamicin

DRUG: Daunorubicin Hydrochloride

DRUG: Fludarabine Phosphate

DRUG: Idarubicin Hydrochloride

DRUG: Mitoxantrone Hydrochloride

DRUG: Etoposide

DRUG: Gilteritinib

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previ...

This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic tri...

DRUG: Arsenic Trioxide

DRUG: Gemtuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Tretinoin

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete ...

DRUG: BP1001 in combination with Ventoclax plus decitabine

DRUG: BP1001 plus decitabine

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults...

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Busulfan

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Methotrexate

PROCEDURE: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome ...

BIOLOGICAL: Cytokine Induced Memory-like Natural Killer Cells

BIOLOGICAL: Interleukin-2

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line th...

DRUG: ADI-PEG 20

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetocla...

This phase I trial tests safety, side effects and best dose of iadademstat with azacitidine and venetoclax for the treatment of patients with acute myeloid leukemia (AML) who have not receive treatment (treatment naive). Chemotherapy drugs, such as i...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Buccal Swab

DRUG: Iadademstat

DRUG: Venetoclax

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for prevention of relapse of childhood myeloid malignanci...

DRUG: Vorinostat

DRUG: Azacitidine Injection

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical T...

This phase I/II pilot study aims to enhance the effectiveness of stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). Patients will undergo a stem cell transplant from a half-matched family donor. One week l...

DRUG: Rabbit Anti thymocyte globulin

DRUG: Busulfan

DRUG: Fludarabine

DRUG: Thiotepa

DRUG: Melphalan

BIOLOGICAL: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft

BIOLOGICAL: memory-like natural killer cells

BIOLOGICAL: IL-2

DRUG: Plerixafor

BIOLOGICAL: Granulocyte Colony-Stimulating Factor

DEVICE: CliniMACS

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic leukemia (ALL) or blastic plasmacytoid dendritic cell neoplasia (BPDCN). The purpose of this ...

DRUG: CD123-CAR T

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

DRUG: Rituximab

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also ...

DRUG: Itacitinib

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs,...

To find a recommended dose of ASTX727 (cedazuridine/decitabine) in combination with venetoclax for pediatric patients with relapsed AML.

DRUG: ASTX727

DRUG: Venetoclax

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myel...

Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute mye...

BIOLOGICAL: UCART123v1.2

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or ...

Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed...

DRUG: CC-91633

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly...

The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitid...

DRUG: Cusatuzumab

DRUG: Venetoclax

DRUG: Azacitidine

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia

This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Onvansertib is ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Onvansertib

PROCEDURE: Ultrasound Imaging

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed,...

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been tre...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

DRUG: Venetoclax

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochlor...

This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelo...

DRUG: Cytarabine

DRUG: Decitabine

BIOLOGICAL: Filgrastim-sndz

DRUG: Fludarabine Phosphate

DRUG: Gemtuzumab Ozogamicin

DRUG: Idarubicin

OTHER: Laboratory Biomarker Analysis

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemi...

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.

DRUG: Vyxeos

DRUG: Venetoclax

Natural Killer Cell (CYNK-001) Infusions in Adults With AML

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemoth...

BIOLOGICAL: CYNK-001

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukem...

This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improv...

DRUG: Eltanexor

DRUG: Venetoclax

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Biospecimen Collection

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myelopr...

This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL m...

DRUG: Azacitidine

DRUG: Quizartinib

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 ...

This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Enasidenib

DRUG: Enasidenib Mesylate

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypome...

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to exceed 10 days if postponement is required to all...

DRUG: Tagraxofusp (Cycles 1-2)

DRUG: Azacitidine

DRUG: Tagraxofusp (Cycles 3-12)

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

DRUG: Clofarabine

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Cyclosporine-A

DRUG: Mycophenolate Mofetil

BIOLOGICAL: Cord Blood Graft

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion c...

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Mitoxantrone

(Apex) Bezuclastinib in Patients with Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cel...

DRUG: bezuclastinib

Azacitidine and Enasidenib in Treating Patients with IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes n...

DRUG: Azacitidine

DRUG: Enasidenib

OTHER: Quality-of-Life Assessment

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis wit...

The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related ...

DRUG: Decitabine

DRUG: Filgrastim

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Ph...

To compare an investigational oral form of the drug cladribine to the FDA approved form of the drug when it is given by vein (IV).

DRUG: Cladribine

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and M...

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drug...

DRUG: Busulfan

DRUG: Cladribine

DRUG: Fludarabine Phosphate

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Thiotepa

DRUG: Venetoclax

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction Wi...

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made...

DRUG: Cyclophosphamide

DRUG: CAR.70/IL15-transduced CB-NK cells

DRUG: Fludarabine phosphate

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety ...

This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through...

DRUG: Talazoparib

DRUG: Topotecan

DRUG: Gemcitabine

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and...

DRUG: SEA-CD70

DRUG: azacitidine

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia wi...

BIOLOGICAL: Samalizumab (BAML-16-001-S1)

BIOLOGICAL: BI 836858 (BAML-16-001-S2)

OTHER: Laboratory Biomarker Analysis

DRUG: Daunorubicin (BAML-16-001-S1)

DRUG: Cytarabine (BAML-16-001-S1)

DRUG: Azacitidine (BAML-16-001-S2)

DRUG: AG-221 (BAML-16-001-S3)

DRUG: Azacitidine (BAML-16-001-S3)

DRUG: Entospletinib (BAML-16-001-S4)

DRUG: Azacitidine (BAML-16-001-S4)

DRUG: Entospletinib (BAML-16-001-S5)

DRUG: Decitabine (BAML-16-001-S5)

DRUG: Entospletinib (BAML-16-001-S6)

DRUG: Daunorubicin (BAML-16-001-S6)

DRUG: Cytarabine (BAML-16-001-S6)

DRUG: Pevonedistat (BAML-16-001-S9)

DRUG: Azacitidine (BAML-16-001-S9)

DRUG: AG-120 (BAML-16-001-S16)

DRUG: Azacitidine (BAML-16-001-S16)

DRUG: Gilteritinib (BAML-16-001-S8 Group 1)

DRUG: Decitabine (BAML-16-001-S8 Group 1)

DRUG: AZD5153 (BAML-16-001-S10)

DRUG: Venetoclax (BAML-16-001-S10)

DRUG: TP-0903 (BAML-16-001-S14)

DRUG: Decitabine (BAML-16-001-S14)

DRUG: Decitabine (BAML-16-001-S8 Group 2)

DRUG: Venetoclax (BAML-16-001-S8 Group 2)

DRUG: AZD5991 (BAML-16-001-S18)

DRUG: Azacitidine (BAML-16-001-S18)

DRUG: SNDX-5613 (BAML-16-001-S17)

DRUG: Azacitidine (BAML-16-001-S17)

DRUG: Venetoclax (BAML-16-001-S17)

DRUG: Gilteritinib (BAML-16-001-S8 Group 2)

DRUG: Venetoclax (BAML-16-001-S12 Arm A)

DRUG: Azacitidine (BAML-16-001-S12 Arm A)

DRUG: Venetoclax (BAML-16-001-S12 Arm B)

DRUG: Azacitidine (BAML-16-001-S12 Arm B)

DRUG: ZE46-0134 (BAML-16-001-S21)

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refract...

BIOLOGICAL: Anti-CD33 CAR T-cells

PROCEDURE: Lymphodepletion Therapy

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

This study will evaluate the safety and tolerability of oral KPT-9274 for the treatment of patients with relapsed or refractory acute myeloid leukemia.

DRUG: KPT-9274

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. O...

BIOLOGICAL: ADCLEC.syn1 CAR T cells

DRUG: Conditioning chemotherapy

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Ne...

This phase II trial studies how well CPX-351 or the CLAG-M regimen (consisting of the drugs cladribine, cytarabine, G-CSF, and mitoxantrone) works in treating medically less-fit patients with acute myeloid leukemia or other high-grade myeloid neoplas...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

DRUG: Cladribine

DRUG: Cytarabine

BIOLOGICAL: Recombinant Granulocyte Colony-Stimulating Factor

DRUG: Mitoxantrone

OTHER: Questionnaire Administration

OTHER: Quality-of-Life Assessment

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnos...

This phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH1 or IDH2 genes (IDH mutated). Ivosidenib is in a ...

DRUG: Azacitidine

PROCEDURE: Biopsy

DRUG: Enasidenib

DRUG: Ivosidenib

DRUG: Venetoclax

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the fol...

DRUG: Cytarabine

DRUG: Idarubicin

DRUG: Daunorubicin

DRUG: Liposomal daunorubicin and cytarabine

DRUG: Venetoclax

DRUG: Azacitidine

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

DRUG: Fludarabine

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Cyclophosphamide

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Melphalan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Diagnostic Imaging

PROCEDURE: Biospecimen Collection

2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML

This clinical research study is being done to answer questions about how to treat cancer. To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons. The protein STING (for STimulator of INterferon ...

DRUG: CRD3874

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase M...

This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemoth...

DRUG: Decitabine

DRUG: Ruxolitinib

DRUG: Fedratinib

OTHER: Questionnaire Administration

DRUG: Pacritinib

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutate...

This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic l...

DRUG: Azacitidine

DRUG: Gilteritinib

DRUG: Venetoclax

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia ...

This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may ...

DRUG: Azacitidine

DRUG: Enasidenib Mesylate

Cord Blood Transplant in Adults With Blood Cancers

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the ...

DRUG: Conditioning Chemotherapy

BIOLOGICAL: Cord blood graft

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults with Relapsed/Refractory AML,...

This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX...

DRUG: MRX-2843

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. I...

DRUG: Purified regulatory T-cells (Treg) plus CD34+ HSPC

DRUG: Fludarabine

DRUG: Melphalan

DEVICE: CliniMACS CD34 Reagent System

DRUG: Tacrolimus

DRUG: Cyclophosphamide

DRUG: Plerixafor

DRUG: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent

DRUG: Thiotepa

DRUG: Mycophenolate Mofetil (MMF)

DRUG: Ruxolitinib

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Pa...

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine

DRUG: Hydrocortisone Sodium Succinate

BIOLOGICAL: Imetelstat

DRUG: Leucovorin Calcium

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syn...

The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid l...

DRUG: CTX-712

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic...

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking so...

DRUG: Azacitidine

DRUG: Seclidemstat

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML...

DRUG: Bleximenib

DRUG: Venetoclax (VEN)

DRUG: Azacitidine (AZA)

DRUG: Cytarabine

DRUG: Daunorubicin or Idarubicin

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemoth...

The primary purpose of this study is to determine complete remission rate of a novel combination induction chemotherapy treatment based upon 20 patients with newly diagnosed secondary AML.

DRUG: Venetoclax

DRUG: FLAG or CLAG Protocol

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NEROFE in patients with MDS or AML. IV NEROFE will be administered three times per week on alte...

DRUG: Nerofe

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Re...

This phase II trial tests how well decitabine and cedazuridine (DEC-C) works in combination with venetoclax in treating acute myeloid leukemia (AML) in patients whose AML has come back after a period of improvement (relapse) after a donor stem cell t...

DRUG: Venetoclax

DRUG: Decitabine

DRUG: Cedazuridine

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Biospecimen Collection

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

This is a Phase 1b, open-label study evaluating Venetoclax in combination with intensive induction and consolidation chemotherapy in previously untreated, adult patients with acute myeloid leukemia. In Part 1, the dose escalation phase, the safety an...

DRUG: Venetoclax Oral Tablet

DRUG: Daunorubicin

DRUG: Cytarabine

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes...

This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients (Arm A) or future HSCT recipients (Arm B) for the treatment...

BIOLOGICAL: Tumor associated antigen lymphocytes (TAA-T)

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Venetoclax to Augment Epigenetic Modification and Chemotherapy

The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.

DRUG: Venetoclax

DRUG: Azacitadine

DRUG: Vorinostat

DRUG: Cytarabine

DRUG: Fludarabine

DRUG: Filgrastim

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), Hi...

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax

DRUG: Azacitidine

DRUG: SL-401

DRUG: Venetoclax

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Mye...

To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.

DRUG: Decitabine

DRUG: Listaftoclax

DRUG: Olverembatinib

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignan...

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant pe...

PROCEDURE: TCRαβ+/CD19+ depleted Haploidentical HSCT

DRUG: Zoledronate

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Natural killer cells are a type of i...

DRUG: Cytarabine Hydrochloride

DRUG: Fludarabine

BIOLOGICAL: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

To find a recommended dose of HC-7366 that can be given in combination with azacitidine and venetoclax to patients with AML. The safety and effects of this drug combination will also be studied.

DRUG: HC-7366

DRUG: Azacitidine

DRUG: Venetoclax

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, e...

DRUG: CPX-351

Venetoclax Basket Trial for High Risk Hematologic Malignancies

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic sy...

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Hydrocortisone

DRUG: Leucovorin

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Dexrazoxane

DRUG: Calaspargase Pegol

DRUG: Erwinia asparaginase

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adul...

The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combinati...

DRUG: gilteritinib

DRUG: fludarabine

DRUG: cytarabine

DRUG: granulocyte colony-stimulating factor (G-CSF)

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azac...

This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.

DRUG: Ziftomenib

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Daunorubicin

DRUG: Cytarabine

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a s...

DRUG: APG-115

DRUG: 5-azacitidine

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatmen...

This phase Ib/II trials studies the side effects of decitabine/cedazuridine (ASTX727) and venetoclax in combination with ivosidenib or enasidenib, and how well they work in treating patients with acute myeloid leukemia that has come back (relapsed) o...

DRUG: Decitabine and Cedazuridine

DRUG: Enasidenib

DRUG: Ivosidenib

DRUG: Venetoclax

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Ven...

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Venetoclax

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid L...

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations...

DRUG: SNDX-5613

DRUG: Chemotherapy Regimen

DRUG: HiDAC

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refrac...

This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not resp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Calaspargase Pegol

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

DRUG: Hydrocortisone Sodium Succinate

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Prednisolone

DRUG: Prednisone

DRUG: Revumenib

DRUG: Vincristine Sulfate

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloi...

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, ...

DRUG: Ziftomenib

DRUG: Fludarabine

DRUG: Idarubicin

DRUG: Cytarabine

DRUG: Gilteritinib

BIOLOGICAL: Granulocyte colony-stimulating factor

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclopho...

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell trans...

DRUG: Busulfan

DRUG: Fludarabine

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

DRUG: Melphalan

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

PROCEDURE: Bone Marrow Hematopoietic Stem Cell Transplantation

DRUG: Post-transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient-Reported Outcomes

DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome...

This phase I trial tests the safety, side effects and best dose of decoy-resistant interleukin-18 (DR-18) and how well it works in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back after a period...

BIOLOGICAL: Decoy-resistant interleukin-18

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Pa...

This is an open-label Phase Ia/Ib clinical study of tagraxofusp-erzs, a novel cytokine-drug conjugate that links interleukin-3 with a truncated diphtheria toxin, in combination with gemtuzumab ozogamicin for patients with relapsed/refractory AML. Th...

DRUG: Dose Escalation -tagraxofusp-erzs

DRUG: Dose Expansion at RP2D -tagraxofusp-erzs

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Un...

This phase II trial studies how well venetoclax, cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated. Drugs used in chemotherapy, such as venetoclax, cladribine, ...

DRUG: Azacitidine

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Venetoclax

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloprolif...

This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syn...

BIOLOGICAL: Axatilimab

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

OTHER: Survey Administration

Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute My...

This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed). Quizartinib may stop the gro...

DRUG: Decitabine

DRUG: Quizartinib

DRUG: Venetoclax

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Ph...

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cance...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

DRUG: Ruxolitinib

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission ...

DRUG: Gilteritinib

DRUG: Vyxeos

Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory ...

This phase I trial tests the safety, side effects, and best dose of palbociclib or tazemetostat in combination with CPX-351 in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or does not respond to treatment (refract...

DRUG: Tazemetostat

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Biospecimen Collection

DRUG: Palbociclib

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From He...

Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains

DRUG: Oral Azacitidine

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalat...

DRUG: CC-96191

Cladribine Venetoclax in Monocytic AML

Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax

DRUG: Cladribine

DRUG: Venetoclax

DRUG: Azacitidine

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transpla...

This phase II trials studies the effect of treosulfan-based versus clofarabine-based conditioning regimens before donor hematopoietic stem cell transplant in treating patients with myelodysplastic syndromes or acute myeloid leukemia. Chemotherapy dru...

DRUG: Clofarabine

DRUG: Fludarabine

PROCEDURE: Hematopoietic Cell Transplantation

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Lumbar Puncture

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Biospecimen Collection

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: * Dendritic Cell/AML Fusion vacci...

DRUG: decitabine

BIOLOGICAL: DC/AML fusion cells

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute My...

This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemothe...

DRUG: Gemtuzumab Ozogamicin

OTHER: Quality-of-Life Assessment

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient...

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

DRUG: Cyclophosphamide

DRUG: Cyclosporine

PROCEDURE: Diagnostic Imaging

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

OTHER: Survey Administration

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplasti...

This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia who have not received...

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutati...

A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or refractory AML.

DRUG: DSP-5336

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Background: Myelodysplastic syndromes (MDS) are diseases that affect the bone marrow. They can inhibit the blood formation process and reduce blood cell counts. High-risk MDS can lead to leukemia. People with high-risk MDS have a low survival rate. ...

DRUG: KPT-8602

DRUG: Inqovi

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With R...

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

DRUG: SAR443579

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloi...

This will be a single arm, open label Phase Ib dose-escalation study of the combination of VEN and OM, conducted using an innovative Bayesian Optimal Interval-design, to find the MTD in participants with AML failing treatment with venetoclax-containi...

DRUG: Omacetaxine

DRUG: Venetoclax

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors

This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care. The information learned in this study may help them know if adding immunotherapy (a type of treatment that ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

OTHER: Electronic Health Record Review

OTHER: Photography

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelody...

This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelody...

DRUG: BTX-A51

DRUG: Azacitidine

This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Busulfan

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Haploidentical Hematopoietic Cell Transplantation

BIOLOGICAL: Lapine T-Lymphocyte Immune Globulin

PROCEDURE: Lumbar Puncture

PROCEDURE: Matched Unrelated Donor Hematopoietic Cell Transplantation

DRUG: Melphalan

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

PROCEDURE: Myeloablative Conditioning

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

PROCEDURE: T-Cell Depletion Therapy

DRUG: Tacrolimus

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Tra...

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it a...

DRUG: Busulfan

DRUG: Fludarabine

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

DRUG: Post-Transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient Reported Outcomes

DRUG: Melphalan

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, M...

This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and...

DRUG: Venetoclax

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Decitabine/cedazuridine

PLAT-08: a Study of SC-DARIC33 CAR T Cells in Pediatric and Young Adults with Relapsed or Refractory...

A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility...

BIOLOGICAL: SC-DARIC33

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial.

DRUG: mocravimod

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients Wit...

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocyti...

DEVICE: Miltenyi CliniMACS Prodigy ® system

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With ...

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase ...

DRUG: Bexmarilimab

DRUG: Azacitidine

DRUG: Venetoclax

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukem...

This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1...

DRUG: Emavusertib

DRUG: Venetoclax

DRUG: Emavusertib

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit N...

An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal to...

DRUG: BST-236

DRUG: venetoclax

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid...

This phase Ib trial tests the safety, side effects, and best dose of a enasidenib in combination with cobimetinib in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Enasidenib...

DRUG: Cobimetinib

DRUG: Enasidenib Mesylate

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malig...

BIOLOGICAL: Orca-Q

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell ...

This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional ex...

PROCEDURE: Graft cell infusion

DRUG: Tacrolimus

DRUG: Mycophenolate mofetil

DRUG: G-CSF

PROCEDURE: CIML NK cell infusion

DRUG: ALT-803

PROCEDURE: Leukapheresis

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malign...

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

BIOLOGICAL: OrcaGraft (Orca-Q)

Olutasidenib for the Treatment of Patients with IDH1 Mutated AML, MDS or CMML After Donor Hematopoie...

This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid leukemia (AML), myelo...

PROCEDURE: Biospecimen Collection

DRUG: Olutasidenib

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia,...

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as c...

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Gilteritinib

DRUG: Idarubicin

OTHER: Laboratory Biomarker Analysis

DRUG: Midostaurin

DRUG: Venetoclax

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantat...

This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the rel...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Fludarabine Phosphate

BIOLOGICAL: Granulocyte Colony-Stimulating Factor

PROCEDURE: Hematopoietic Cell Transplantation

PROCEDURE: Intensity-Modulated Radiation Therapy

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron...

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chro...

DIETARY_SUPPLEMENT: Ascorbic Acid

DRUG: Carboplatin

DRUG: Cisplatin

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: Gemcitabine Hydrochloride

DRUG: Ifosfamide

OTHER: Laboratory Biomarker Analysis

DRUG: Oxaliplatin

OTHER: Placebo Administration

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Decitabine

PROCEDURE: Biospecimen Collection

PROCEDURE: Core Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Central Venous Cannula Insertion

PROCEDURE: Portacath Placement

PROCEDURE: Computed Tomography

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted stand...

DRUG: NMS-03597812

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study...

DEVICE: CliniMACS

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelody...

This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The safety of this drug combination will also be studied. IDH1 is a t...

DRUG: Ivosidenib

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostauri...

This phase I study hopes to explore how safe and tolerable is the combination of gemtuzumab ozogamicin (GO) and midostaurin, with the standard induction therapy (cytarabine and daunorubicin) in patients with newly diagnosed FLT-3 mutated Acute Myeloi...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Gemtuzumab Ozogamicin

DRUG: Midostaurin

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in...

This phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia. Chemotherapy drugs, such as cytarabine, idarubicin, and daunorubicin, ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

PROCEDURE: Echocardiography

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Idarubicin Hydrochloride

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Pembrolizumab

PROCEDURE: Punch Biopsy

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.

DRUG: LY3214996

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute ...

This phase I trial tests the safety, side effects, and best dose of entrectinib when given with ASTX727 in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or that does not respond to treatment (refractory) and has a ...

DRUG: Decitabine and Cedazuridine

DRUG: Entrectinib

OTHER: Laboratory Biomarker Analysis

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Ne...

This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination therapy in treating p...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Idarubicin

PROCEDURE: Multigated Acquisition Scan

DRUG: Pivekimab Sunirine

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leu...

Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing. Objectives: - To find ...

DRUG: TURALIO(R)

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

DRUG: VIP943 (QW)

DRUG: VIP943 (BIW)

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adu...

This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The tri...

BIOLOGICAL: CD33CART autologous

BIOLOGICAL: CD33CART allogeneic

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acu...

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunor...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

PROCEDURE: Echocardiography

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

PROCEDURE: Multigated Acquisition Scan

DRUG: Venetoclax

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 M...

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to det...

DRUG: revumenib

DRUG: cobicistat

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML Afte...

This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte ant...

BIOLOGICAL: VCAR33

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

DRUG: Niclosamide

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is...

DRUG: BXCL701

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count,...

DRUG: Hyperbaric oxygen

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.

DRUG: Bomedemstat

DRUG: Venetoclax

DEC-C and Thioguanine for R/R AML

The purpose of this study is to find out if oral decitabine-cedazuridine (Inqovi®) is effective, safe, and able to be tolerated without severe side effects when given with thioguanine (Tabloid®) in patients with acute myeloid leukemia (AML) whose dis...

DRUG: Thioguanine (Tabloid ®)

DRUG: DecitabineCedazuridine (Inqovi ®)

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in diff...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Ch...

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and...

BIOLOGICAL: CD4CAR

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose ...

DRUG: APG 2575 ramp up arm

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML...

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mut...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Gilteritinib

DRUG: Venetoclax

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daun...

This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

DRUG: Daunorubicin

PROCEDURE: Multigated Acquisition Scan

DRUG: Revumenib

PROCEDURE: Transthoracic Echocardiography

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells that have been engineered to recognize and attack y...

BIOLOGICAL: CD33KO-HSPC; CART33

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

CD123 Redirected T Cells for AML in Pediatric Subjects

Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects...

BIOLOGICAL: CART123 cells; cyclophosphamide; fludarabine

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of zif...

DRUG: Ziftomenib

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or...

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

DRUG: BMS-986497

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory acute myeloid leukemia. PRIMARY OBJECTIVE: I. To...

BIOLOGICAL: Universal Donor Natural Killer Cells

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myel...

DRUG: ABL001

DRUG: Dasatinib

DRUG: Prednisone

DRUG: Blinatumomab

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Melphalan

DRUG: Rituximab

DRUG: Levetiracetam

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide,...

This phase I trial studies the best dose and side effects of M3814 when given in combination with mitoxantrone, etoposide, and cytarabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiogram Recording

DRUG: Etoposide Phosphate

DRUG: Mitoxantrone Hydrochloride

PROCEDURE: Multigated Acquisition Scan

DRUG: Peposertib

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixe...

DRUG: Vyxeos

DRUG: Gemtuzumab Ozogamicin

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Ac...

This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood ...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Tacrolimus

BIOLOGICAL: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs

DRUG: Methotrexate

DRUG: Cyclophosphamide

BIOLOGICAL: Peripheral Blood Stem Cell

DRUG: Cyclosporine

DRUG: Sirolimus

DRUG: Busulfan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Biospecimen Collection

Ziftomenib Maintenance Post Allo-HCT

The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study pla...

DRUG: Ziftomenib

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoieti...

Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant (allo-HCT). However, the complete remission (CR) rates and l...

DRUG: CIML NK Cell Infusion

PROCEDURE: CD3+ T Cell Product Infusion

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relap...

This phase I/II trial studies the side effects and how well cladribine, idarubicin, cytarabine, and quizartinib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that is newly diagnosed, has come back (relaps...

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Idarubicin

DRUG: Quizartinib

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chron...

This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back ...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant ...

This phase I studies the side effects and best dose of total marrow and lymphoid irradiation when given together with fludarabine and melphalan before donor stem cell transplant in treating participants with high-risk acute leukemia or myelodysplasti...

DRUG: Fludarabine

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

RADIATION: Total Marrow Irradiation

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HC...

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).

BIOLOGICAL: VOR33

DRUG: Mylotarg

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or Hig...

The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

BIOLOGICAL: SPRX002

BIOLOGICAL: ARC-T Cells

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agen...

This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitid...

DRUG: Azacitidine

DRUG: Decitabine

DRUG: Venetoclax

IS-free Treg HaploHCT

This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) rec...

RADIATION: Radiation

DRUG: Fludarabine

DRUG: Thiotepa

DRUG: Cyclophosphamide

DRUG: Mesna

BIOLOGICAL: Treg-enriched donor cell

BIOLOGICAL: Unmodified donor T Cell

PROCEDURE: CD34+ Haplo Peripheral Blood Stem Cell

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refr...

This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen and followed at periodi...

DRUG: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen

DRUG: Cladribine and Cytarabine (CLLDAC) Regimen

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Settin...

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survi...

DRUG: Azacitidine

DRUG: Venetoclax

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVE...

To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.

DRUG: Azacitidine

DRUG: Venetoclax

DRUG: NK Cells

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute My...

CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in ...

DRUG: CB-012

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). \[(FDA OOPD)\]

DRUG: Danvatirsen

COMBINATION_PRODUCT: Danvatirsen + Venetoclax

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic ...

This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not ...

DRUG: Akt/ERK Inhibitor ONC201

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leuk...

This phase Ib trial studies the side effects and best dose of pembrolizumab and how well it works in combination with decitabine with or without venetoclax in treating patients with acute myeloid leukemia or myelodysplastic syndrome that is newly-dia...

DRUG: Decitabine

BIOLOGICAL: Pembrolizumab

DRUG: Venetoclax

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral c...

DRUG: DFP-10917

DRUG: Venetoclax

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating W...

To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Venetoclax

DRUG: Azacitidine

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSC...

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive...

DRUG: Tagraxofusp

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and...

Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Sometimes these transplants cause serious side effects,...

DRUG: Melphalan

DRUG: Sirolimus

RADIATION: Total Body Irradiation (TBI)

DRUG: Cyclophosphamide

DRUG: Mycophenolate Mofeti

DRUG: Fludarabine

PROCEDURE: Allogeneic HSCT

DRUG: Mesna

DRUG: Filgrastim

Study of REM-422 in Patients With AML or Higher Risk MDS

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

DRUG: REM-422

NTX-301 in MDS/AML

NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.

DRUG: NTX-301

Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patie...

This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

BIOLOGICAL: Filgrastim

OTHER: Laboratory Biomarker Analysis

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Tacrolimus

RADIATION: Total Marrow Irradiation

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.

DRUG: SGR-2921

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Le...

This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refrac...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Gilteritinib

DRUG: Revumenib

CART-38 in Adult AML and MM Patients

This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patien...

DRUG: 3x10(6) CART-38 cellls

DRUG: 7x10(5) CART-38 cells

DRUG: 7x10(6) CART-38 cells

DRUG: 3x10(7) CART-38 cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" \[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)\] in the treatment of acute myeloid leukemia (AML) that has n...

DRUG: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutatio...

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a ...

DRUG: Iadademstat

DRUG: Gilteritinib Oral Tablet

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patie...

This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have ...

DRUG: Fludarabine Phosphate

DRUG: Melphalan

RADIATION: Intensity-Modulated Radiation Therapy

RADIATION: Total Marrow Irradiation

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Peripheral Blood Stem Cell Transplantation

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Laboratory Biomarker Analysis

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion wi...

DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnos...

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed...

DRUG: Gilteritinib

DRUG: Venetoclax

DRUG: Azacitidine

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Partic...

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relap...

DRUG: ABBV-787

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maint...

This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission...

DRUG: Decitabine and Cedazuridine

DRUG: Enasidenib

DRUG: Gilteritinib

DRUG: Ivosidenib

DRUG: Venetoclax

CC-486 and Venetoclax for Acute Myeloid Leukemia

This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recomme...

DRUG: Venetoclax

DRUG: CC-486

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

This research study uses special blood cells called multiple tumor-associated antigen (TAA)-specific T cells (a new experimental therapy) to treat patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) which has come back, or ma...

BIOLOGICAL: MultiTAA-specific T cells

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid ...

The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML). A secondary objective is...

DRUG: CIML-NK Cells

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mut...

To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.

DRUG: Gilteritinib

DRUG: Momelotinib

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3...

DRUG: Decitabine

BIOLOGICAL: Tagraxofusp-erzs

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

DRUG: BMF-500

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation fo...

This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating patients with high-risk ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Basiliximab

DRUG: Fludarabine Phosphate

DRUG: Indium In 111-DOTA-Basiliximab

DRUG: Melphalan

BIOLOGICAL: Palifermin

RADIATION: Total Lymphoid Irradiation

RADIATION: Total Marrow Irradiation

BIOLOGICAL: Yttrium Y 90 Basiliximab

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid...

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. the study will evaluate safety in this patient popu...

BIOLOGICAL: CD4CAR

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic...

This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies

BIOLOGICAL: CTX131

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromos...

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respo...

BIOLOGICAL: Blinatumomab

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Ponatinib

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow an...

This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatm...

BIOLOGICAL: Actinium Ac 225-DOTA-Daratumumab

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Hematopoietic Cell Transplantation

BIOLOGICAL: Indium In 111-DOTA-Daratumumab

DRUG: Melphalan

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Radionuclide Imaging

PROCEDURE: Single Photon Emission Computed Tomography

DRUG: Sirolimus

DRUG: Tacrolimus

RADIATION: Total Marrow and Lymphoid Irradiation

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractor...

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lin...

DRUG: Revumenib

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: intrathecal (IT) chemotherapy

DRUG: Cytarabine

DRUG: Methotrexate

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and...

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic an...

DRUG: EAGD T-cell infusion (Phase I)

DRUG: EAGD T-cell infusion (Expansion)

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

DRUG: Daunorubicin

PROCEDURE: Electrocardiography

DRUG: Pemigatinib

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted...

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is...

DEVICE: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid L...

This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or elderly patients with newly diagnosed acute m...

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplast...

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1 (Dose Es...

DRUG: BH-30236

Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutatio...

This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blockin...

DRUG: Enasidenib Mesylate

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Me...

To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

DRUG: Venetoclax

DRUG: Revumenib

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determin...

An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy follow...

BIOLOGICAL: CYAD-02

DRUG: ENDOXAN

DRUG: Fludara

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

DRUG: CFI-400945

DRUG: Azacitidine

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone...

The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced inten...

OTHER: Ossium HPC Marrow, Bone Marrow Transplant

OTHER: Pre-transplant conditioning - Myeloablative (MAC)

OTHER: Pre-transplant conditioning - Reduced Intensity (RIC)

OTHER: Post-transplant treatment

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrom...

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

DRUG: CLN-049

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant uti...

DRUG: Busulfan

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: rabbit ATG

DRUG: G-CSF

BIOLOGICAL: Peripheral blood stem cell

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of c...

DRUG: Azacitidine

DRUG: Venetoclax

Chimeric Antigen Receptor T-cells for the Treatment of AML Expressing CLL-1 Antigen

Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of fighting disease and infection, and this research study combines two d...

BIOLOGICAL: CLL-1.CAR T cells

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (B...

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor

DRUG: Blinatumomab

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve...

This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). The drugs involved in this study are: * Venetoclax * Daunorubicin * Cytarabine

DRUG: Venetoclax

DRUG: Daunorubicin

DRUG: Cytarabine

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemi...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

BIOLOGICAL: Ipilimumab

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

BIOLOGICAL: CD371-specific/YSNVz/I-18 CAR T cells

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who ...

DRUG: Fludarabine

DRUG: Cytarabine

DRUG: Gemtuzumab Ozogamicin

DRUG: Azacitidine

DRUG: Venetoclax

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute M...

This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Dual-Energy Computed Tomography

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Magnetic Resonance Imaging

DRUG: Melphalan

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201

DRUG: Tacrolimus

DRUG: Thiotepa

RADIATION: Total Marrow and Lymphoid Irradiation

Pacritinib in CMML

This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who ha...

DRUG: Pacritinib

DRUG: Azacitidine

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myel...

This phase 2 study aims to confirm the efficacy seen in the prior phase 1 trial, and further contribute to this effort through the collection of leukemia cells pre- and post- in vivo IFN-γ therapy. As in the previously conducted phase 1 trial, this t...

DRUG: Interferon gamma-1b

BIOLOGICAL: Donor Leukocyte Infusion (DLI)

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patien...

This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludar...

BIOLOGICAL: Dilanubicel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

OTHER: Laboratory Biomarker Analysis

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Electrocardiography

PROCEDURE: Computed Tomography

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants...

This is a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or adult participants with CD...

BIOLOGICAL: SAR443579

DRUG: venetoclax

DRUG: azacitidine

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a ye...

DRUG: Azacitidine

DRUG: Decitabine

DRUG: Venetoclax

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Fo...

This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and myelodysplastic syndrome (...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

OTHER: Questionnaire Administration

BIOLOGICAL: Tagraxofusp-erzs

Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Ri...

This phase II trial studies the safety and efficacy of total marrow and lymphoid irradiation (TMLI) in combination with two chemotherapy drugs, etoposide and cyclophosphamide, as a preparative regimen before donor stem cell transplant in treating pat...

DRUG: etoposide

DRUG: cyclophosphamide

RADIATION: total marrow irradiation

PROCEDURE: allogeneic hematopoietic stem cell transplantation

PROCEDURE: allogeneic bone marrow transplantation

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for th...

This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy reduced-intensity condition...

DRUG: Cladribine

DRUG: Cyclophosphamide

DRUG: Cyclosporine

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Mitoxantrone

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Idarubicin

DRUG: Fludarabine

DRUG: Cytarabine

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Echocardiography

PROCEDURE: X-Ray Imaging

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Biospecimen Collection

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic ...

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies ...

DRUG: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)

DEVICE: JH-DSA Semi-Quant Screen and Response Score

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 ...

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose e...

DRUG: AG-120

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After I...

This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a comb...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

A Study of BGB-11417 in Participants With Myeloid Malignancies

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome...

DRUG: BGB-11417

DRUG: Azacitidine

DRUG: Posaconazole

DRUG: BGB-11417

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or W...

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS...

DRUG: LYT-200

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Decitabine

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed t...

DRUG: MGD024

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodyspla...

This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to l...

DRUG: Edetate Calcium Disodium

DIETARY_SUPPLEMENT: Multivitamin

DRUG: Succimer

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Re...

This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia that has come back o...

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Idarubicin

BIOLOGICAL: Pegfilgrastim

DRUG: Venetoclax

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Le...

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter \[NIS\]) with or without cyclophosphamide or ipilimumab and nivolumab ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

DRUG: HMPL-306

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid...

This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may ...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

DRUG: Iadademstat

PROCEDURE: Multigated Acquisition Scan

OTHER: Questionnaire Administration

DRUG: Venetoclax

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspet...

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 ...

DRUG: Tuspetinib

DRUG: Venetoclax Oral Tablet

DRUG: Azacitidine for Intravenous Infusion

Venetoclax and Lintuzumab-Ac225 in AML Patients

The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage ...

BIOLOGICAL: Lintuzumab-Ac225

DRUG: Venetoclax

DRUG: Spironolactone

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory...

This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children ...

DRUG: Luveltamab tazevibulin

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Deci...

Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML...

DRUG: SNDX-5613

DRUG: Venetoclax

DRUG: ASTX727

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloi...

The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied....

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Decitabine

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematol...

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivoside...

DRUG: Azacitidine

DRUG: Ivosidenib

DRUG: Venetoclax

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Pha...

DRUG: Bleximenib

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Pati...

The purpose of this study is to test the safety and determine the best dose of venetoclax and selinexor when given with chemotherapy drugs in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous...

DRUG: Venetoclax

DRUG: Selinexor

DRUG: Cytarabine

DRUG: Fludarabine

BIOLOGICAL: Filgrastim

DRUG: Methotrexate

DRUG: methotrexate/hydrocortisone/cytarabine

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the bes...

DRUG: GDX012

DRUG: Chemotherapy Agents

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Othe...

This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplasti...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infect...

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Hematopoietic Cell Transplantation Conditioning Regimen

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Pheresis

DRUG: Placebo Administration

DRUG: Stem Cell Mobilization Therapy

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, ...

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cell...

BIOLOGICAL: Canakinumab

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib

DRUG: Ruxolitinib

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid L...

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytar...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

DRUG: Quizartinib

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Ref...

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory highe...

DRUG: GLB-001

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Re...

This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does not respond to treatmen...

DRUG: Gemtuzumab Ozogamicin

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

OTHER: Quality-of-Life Assessment

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory F...

This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib in treating patients with FLT3-mutated acute myeloid leukemia that is newly diagnosed, has ...

DRUG: Decitabine and Cedazuridine

DRUG: Gilteritinib

DRUG: Venetoclax

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematolo...

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory A...

DRUG: SLS009

DRUG: venetoclax

DRUG: azacitidine

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination ...

DRUG: FHD-286

DRUG: Low Dose Cytarabine

DRUG: Decitabine

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).

DRUG: CPX-351

DRUG: MHA

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking som...

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Selinexor

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies

This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation stu...

BIOLOGICAL: DSP107

DRUG: Azacitidine

DRUG: Venetoclax

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

The goal of this clinical research study is to learn about the safety and effectiveness of giving KDS-1001 in combination with a standard stem cell transplant to patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic m...

DRUG: Cyclophosphamide

DRUG: Mesna

DRUG: Filgrastim

DRUG: Melphalan

DRUG: Fludarabine phosphate

DRUG: Tacrolimus

DRUG: Mycophenolate mofetil

DRUG: Total Body Irradiation One Dose

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Get the latest thought leadership on your Acute Myeloid Leukemia delivered straight to your inbox

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info